Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis

BACKGROUND: At the end of 2021, the European Medicines Agency (EMA) expanded its approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the treatment of COVID-19 patients with elevated soluble urokinase plasminogen activator receptor (suPAR). However, the role of An...

Descripción completa

Detalles Bibliográficos
Autores principales: Dahms, Karolina, Mikolajewska, Agata, Ansems, Kelly, Metzendorf, Maria-Inti, Benstoem, Carina, Stegemann, Miriam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959952/
https://www.ncbi.nlm.nih.gov/pubmed/36841793
http://dx.doi.org/10.1186/s40001-023-01072-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959952/
https://www.ncbi.nlm.nih.gov/pubmed/36841793
http://dx.doi.org/10.1186/s40001-023-01072-z

Ejemplares similares